Solventum Corporation logo SOLV - Solventum Corporation

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 9
HOLD 2
SELL 1
STRONG
SELL 0
| PRICE TARGET: $91.13 DETAILS
HIGH: $113.00
LOW: $43.00
MEDIAN: $97.50
CONSENSUS: $91.13
UPSIDE: 7.15%

Stock News

Solventum Announces FDA 510(k) Clearance for Combined Use of Restrata™ Matrix and Solventum™ V.A.C.® Therapy*

Solventum Announces FDA 510(k) Clearance for Combined Use of Restrata™ Matrix and Solventum™ V.A.C.® Therapy*

First-of-its-kind clearance combines two advanced wound care technologies into one path for active healing to help streamline care and improve patient outcomes Clearance pairs innovative synthetic electrospun fiber matrix technology with an industry-leading negative pressure wound therapy to optimize healing EAGAN, Minn., Oct. 19, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV), a leader in advanced wound healing, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the combined use of Restrata™ Synthetic Electrospun Fiber Matrix and Solventum™ V.A.C.

Oct 19, 2026 12:05 PM • prnewswire.com
Stock Picks From Seeking Alpha's September 2026 New Analysts

Stock Picks From Seeking Alpha's September 2026 New Analysts

Seeking Alpha welcomed 38 new analysts in September 2026. This article showcases their top picks and investment strategies. Highlighted companies include Qualcomm, Teladoc, and NewLake Capital Partners, as well as the ETF TDAQ, each with a detailed investment thesis. We invite you all to engage with our new contributing analysts, explore their diverse investment theses, and consider following up on the highlighted stock ideas.

Oct 07, 2026 05:00 AM • seekingalpha.com
Financial Review: Solventum (NYSE:SOLV) vs. NeurAxis (NASDAQ:NRXS)

Financial Review: Solventum (NYSE:SOLV) vs. NeurAxis (NASDAQ:NRXS)

NeurAxis (NASDAQ: NRXS - Get Free Report) and Solventum (NYSE: SOLV - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk. Institutional and Insider Ownership 11.8% of NeurAxis shares are held

Oct 05, 2026 02:15 AM • defenseworld.net
Head to Head Contrast: Solventum (NYSE:SOLV) & Tandem Diabetes Care (NASDAQ:TNDM)

Head to Head Contrast: Solventum (NYSE:SOLV) & Tandem Diabetes Care (NASDAQ:TNDM)

Tandem Diabetes Care (NASDAQ: TNDM - Get Free Report) and Solventum (NYSE: SOLV - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations and profitability. Analyst Ratings This is a breakdown of recent

Sep 29, 2026 10:29 PM • defenseworld.net
Solventum: Divestiture Unlocking Upside In A Spinoff Revaluation Play

Solventum: Divestiture Unlocking Upside In A Spinoff Revaluation Play

Solventum trades at a significant discount to medical technology peers, with a forward P/E of ~13x and suppressed EV/EBITDA multiples. Management is executing a portfolio optimization, including a potential spin-off of the Health Information Systems segment to unlock value and reduce debt. Raised 2026 EPS guidance to $7.10-$7.20 and operating margins to 22.2%-22.7%, signaling margin expansion and improved free cash flow allocation.

Sep 18, 2026 03:41 AM • seekingalpha.com

Price Targets